1. 2294 Growth modulation index (GMI) to assess salvage chemotherapy benefit after FOLFIRINOX progression in metastatic pancreatic adenocarcinoma. (September 2015) Authors: Ducoulombier, A.; Quintin, J.; Desjardin, M.; Hautefeuille, V.; Desauw, C.; Parzy, A.; Bouche, O.; Chauffert, B.; Clisant, S.; El Hajbi, F.; Becouarn, Y.; Bennouna, J.; Hebbar, M.; Penel, N.; Adenis, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S430 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 24‐hour pH‐impedance monitoring on therapy to select patients with refractory reflux symptoms for antireflux surgery. A single center retrospective study. Issue 1 (3rd November 2015) Authors: Desjardin, M.; Luc, G.; Collet, D.; Zerbib, F. Journal: Neurogastroenterology & motility Issue: Volume 28:Issue 1(2016) Page Start: 146 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Chemotherapy does not impair parenchymal sparing surgery to treat colorectal liver metastases. (February 2017) Authors: Evrard, S.; Desjardin, M.; Brouste, V.; Bonhomme, B.; Fonck, M.; Becouarn, Y.; Bechade, D.; Desolneux, G. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗